Core Viewpoint - Maze is presenting data from the Phase I clinical trial of MZE782, an oral SLC6A19 inhibitor aimed at treating phenylketonuria (PKU) in patients with chronic kidney disease (CKD) [1] Group 1 - The event is intended for the investment community and includes forward-looking statements based on current expectations [2] - Management's statements involve assumptions, risks, and uncertainties, with no obligation to update or revise these statements [2] - The presentation will feature introductory remarks from the CEO, followed by a review of Phase I clinical data by the Chief Medical Officer [3]

Core Insights - The article discusses a significant advancement in chronic kidney disease (CKD) diagnosis through a non-invasive model utilizing retinal images, developed by a research team from Sun Yat-sen University [2][3][6]. Group 1: Research Development - The Kidney Intelligent Diagnosis System (KIDS) was created to predict kidney biopsy outcomes non-invasively, achieving an area under the curve (AUC) of 0.839-0.993 in CKD screening [3][11]. - KIDS can accurately identify five common pathological types of CKD with an AUC of 0.790-0.932, outperforming nephrologists by 26.98% in accuracy [3][12]. Group 2: Clinical Implications - The non-invasive model has the potential to improve clinical management of CKD, especially for patients who are unsuitable for traditional kidney biopsies [3][16]. - KIDS provides objective pathological and prognostic predictions, which could enhance kidney care quality and reduce the incidence of end-stage renal disease, particularly in underdeveloped regions [16]. Group 3: Background and Challenges - CKD affects approximately 850 million people globally and poses significant health risks, with kidney biopsy being the gold standard for diagnosis but often limited by various factors [6][7]. - Complications from kidney biopsies, such as bleeding, occur in 11% of cases, highlighting the need for safer diagnostic alternatives [6].